Fidelity Investments’s VYNE Therapeutics VYNE Stock Holding History

Fidelity Investments’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5	Closed	-$17	–	5709
2024 Q4	$17	Buy	+5	New	+$13	﹤0.01%	5395
2022 Q1	–	Sell	-83	Closed	-$2K	–	5529
2021 Q4	$2K	Hold	83	–	–	﹤0.01%	4058
2021 Q3	$2K	Buy	+83	New	+$3.22K	﹤0.01%	4058
2019 Q1	–	Sell	-5	Closed	-$1K	–	4266
2018 Q4	$1K	Buy	+5	New	+$2.24K	﹤0.01%	3433
2018 Q3	–	Sell	-15,529	Closed	-$9.08M	–	3822
2018 Q2	$9.08M	Hold	15,529	–	–	﹤0.01%	1974
2018 Q1	$42M	Buy	+15,529	New	+$37.8M	0.01%	1384

Other funds holding VYNE

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Fidelity Investments's VYNE Position: Q1 2025 in Review

Fidelity Investments sold out of VYNE Therapeutics (VYNE) in Q1 2025, closing a stake of 5 shares — an estimated $17 sold.

Fidelity Investments first reported a position in VYNE in Q1 2018 and held it in 6 quarters. The position peaked at $42M in Q1 2018. 38 funds tracked by Wall St. Rank hold VYNE as of Q1 2025.

Fidelity Investments reported no remaining VYNE Therapeutics position as of Q1 2025 after selling out during the quarter.
Fidelity Investments sold 5 VYNE Therapeutics shares in Q1 2025, an estimated $17.
Fidelity Investments first reported a position in VYNE Therapeutics in Q1 2018 and held it in 6 quarters.
Fidelity Investments's VYNE Therapeutics position peaked at $42M in Q1 2018.
38 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2025.

Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.